-
1
-
-
0036280764
-
Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: A possible mechanism for the accumulation of malignant T lymphocytes in the skin
-
Dereure O, Levi E, Vonderheid EC, Kadin ME: Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 2002; 118: 949-956.
-
(2002)
J Invest Dermatol
, vol.118
, pp. 949-956
-
-
Dereure, O.1
Levi, E.2
Vonderheid, E.C.3
Kadin, M.E.4
-
2
-
-
0032212221
-
Prognostic significance of polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides
-
Delfau-Larue MH, Dalac S, Lepage E, Petrella T, Wechsler J, Farcet JP, Bagot M: Prognostic significance of polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood 1998; 92: 3376-3380.
-
(1998)
Blood
, vol.92
, pp. 3376-3380
-
-
Delfau-Larue, M.H.1
Dalac, S.2
Lepage, E.3
Petrella, T.4
Wechsler, J.5
Farcet, J.P.6
Bagot, M.7
-
3
-
-
0034329353
-
Diagnostic value of dominant Tcell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma
-
Delfau-Larue MH, Laroche L, Wechsler J, Lepage E, Lahet C, Asso-Bonnet M, Bagot M, Farcet JP: Diagnostic value of dominant Tcell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood 2000; 96: 2987-2992.
-
(2000)
Blood
, vol.96
, pp. 2987-2992
-
-
Delfau-Larue, M.H.1
Laroche, L.2
Wechsler, J.3
Lepage, E.4
Lahet, C.5
Asso-Bonnet, M.6
Bagot, M.7
Farcet, J.P.8
-
4
-
-
0042964834
-
Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome
-
Kim YH, Liu HL, Mraz-Gernhard S, et al: Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Arch Dermatol 2003; 139: 857-866.
-
(2003)
Arch Dermatol
, vol.139
, pp. 857-866
-
-
Kim, Y.H.1
Liu, H.L.2
Mraz-Gernhard, S.3
-
5
-
-
0035340844
-
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results
-
Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471. (Pubitemid 32391217)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.9
, pp. 2456-2471
-
-
Duvic, M.1
Hymes, K.2
Heald, P.3
Breneman, D.4
Martin, A.G.5
Myskowski, P.6
Crowley, C.7
Yocum, R.C.8
-
6
-
-
0034999546
-
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma
-
Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-593.
-
(2001)
Arch Dermatol
, vol.137
, pp. 581-593
-
-
Duvic, M.1
Martin, A.G.2
Kim, Y.3
Olsen, E.4
Wood, G.S.5
Crowley, C.A.6
-
7
-
-
0036096774
-
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action
-
Zhang C, Hazarika P, Ni X, Weidner D, Duvic M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8: 1234-1240.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1234-1240
-
-
Zhang, C.1
Hazarika, P.2
Ni, X.3
Weidner, D.4
Duvic, M.5
-
8
-
-
21644469232
-
Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy
-
Brennand S, Sutton VR, Biagi J, Trapani JA, Westerman D, McCormack CJ, Seymour JF, Kennedy G, Prince HM: Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy. Br J Dermatol 2005; 152: 1199-1205.
-
(2005)
Br J Dermatol
, vol.152
, pp. 1199-1205
-
-
Brennand, S.1
Sutton, V.R.2
Biagi, J.3
Trapani, J.A.4
Westerman, D.5
McCormack, C.J.6
Seymour, J.F.7
Kennedy, G.8
Prince, H.M.9
-
9
-
-
14944387129
-
Biological effects of bexarotene in cutaneous T-cell lymphoma
-
Budgin JB, Richardson SK, Newton SB, Wysocka M, Zaki MH, Benoit B, Rook AH: Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005; 141: 315-320.
-
(2005)
Arch Dermatol
, vol.141
, pp. 315-320
-
-
Budgin, J.B.1
Richardson, S.K.2
Newton, S.B.3
Wysocka, M.4
Zaki, M.H.5
Benoit, B.6
Rook, A.H.7
-
10
-
-
20844443468
-
WHOEORTC classification for cutaneous lymphomas
-
Willemze R, Jaffe ES, Burg G, et al: WHOEORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
-
(2005)
Blood
, vol.105
, pp. 3768-3785
-
-
Willemze, R.1
Jaffe, E.S.2
Burg, G.3
-
11
-
-
4644340662
-
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series
-
Singh F, Lebwohl MG: Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004; 51: 570-573.
-
(2004)
J Am Acad Dermatol
, vol.51
, pp. 570-573
-
-
Singh, F.1
Lebwohl, M.G.2
-
12
-
-
35848945451
-
Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides
-
Lokitz ML, Wong HK: Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. Photodermatol Photoimmunol Photomed 2007; 23: 255-257.
-
(2007)
Photodermatol Photoimmunol Photomed
, vol.23
, pp. 255-257
-
-
Lokitz, M.L.1
Wong, H.K.2
-
13
-
-
0036827563
-
Optimizing bexarotene therapy for cutaneous T-cell lymphoma
-
Talpur R, Ward S, Apisarnthanarax N, Breuer-McHam J, Duvic M: Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-684.
-
(2002)
J Am Acad Dermatol
, vol.47
, pp. 672-684
-
-
Talpur, R.1
Ward, S.2
Apisarnthanarax, N.3
Breuer-Mcham, J.4
Duvic, M.5
-
14
-
-
66149151028
-
Bexarotene therapy for mycosis fungoides and Sézary syndrome
-
Abbott RA, Whittaker SJ, Morris SL, Russel-Jones R, Hung T, Bashir SJ, Scarisbrick JJ: Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 2009; 160: 1299-1307.
-
(2009)
Br J Dermatol
, vol.160
, pp. 1299-1307
-
-
Abbott, R.A.1
Whittaker, S.J.2
Morris, S.L.3
Russel-Jones, R.4
Hung, T.5
Bashir, S.J.6
Scarisbrick, J.J.7
-
15
-
-
0041307312
-
Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy
-
Ferenczi K, Yawalkar N, Jones D, Kupper TS: Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Arch Dermatol 2003; 139: 909-913.
-
(2003)
Arch Dermatol
, vol.139
, pp. 909-913
-
-
Ferenczi, K.1
Yawalkar, N.2
Jones, D.3
Kupper, T.S.4
-
16
-
-
40649110333
-
TCRgamma-chain gene rearrangement by PCR-based Gene-Scan: Diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples
-
Ponti R, Fierro MT, Quaglino P, Lisa B, Paola FC, Michela O, Paolo F, Comessatti A, Novelli M, Bernengo MG: TCRgamma-chain gene rearrangement by PCR-based Gene-Scan: diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples. J Invest Dermatol 2008; 128: 1030-1038.
-
(2008)
J Invest Dermatol
, vol.128
, pp. 1030-1038
-
-
Ponti, R.1
Fierro, M.T.2
Quaglino, P.3
Lisa, B.4
Paola, F.C.5
Michela, O.6
Paolo, F.7
Comessatti, A.8
Novelli, M.9
Bernengo, M.G.10
-
17
-
-
0032722756
-
Durable loss of malignant T-cell clone in stage IV cutaneous T-cell lymphoma patient treated with high dose interferon and photopheresis
-
Haley HR, Davis DA, Sams WM: Durable loss of malignant T-cell clone in stage IV cutaneous T-cell lymphoma patient treated with high dose interferon and photopheresis. J Am Acad Dermatol 1999; 41: 880-883.
-
(1999)
J Am Acad Dermatol
, vol.41
, pp. 880-883
-
-
Haley, H.R.1
Davis, D.A.2
Sams, W.M.3
-
18
-
-
34249093850
-
Apoptotic responses to alltrans retinoic acid of Targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sézary syndrome
-
Newton SB, Yoon JS, Benoit BM, Wysocka M, Rook AH: Apoptotic responses to alltrans retinoic acid of Targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sézary syndrome. Arch Dermatol 2007; 143: 661-662.
-
(2007)
Arch Dermatol
, vol.143
, pp. 661-662
-
-
Newton, S.B.1
Yoon, J.S.2
Benoit, B.M.3
Wysocka, M.4
Rook, A.H.5
|